Oncology Grand Rounds Series: Part 6 — Emerging Strategies in Non-Small Cell Lung Cancer

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao: Introduction (00:00) Program overview: Dr Love EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) (9:42) Case (Ms Pagtama): A man in his late 50s with Stage IV adenocarcinoma of the lung with an EGFR tumor mutation, a right pleural effusion and a single brain metastasis who received first-line osimertinib (28:51) Case (Ms Goodwin): A woman in her early 70s with Stage IV adenosquamous NSCLC with an EGFR tumor mutation who was found to have a MET amplification after disease progression on osimertinib (33:57) Immune Checkpoint Inhibitor Therapy for Metastatic NSCLC (41:29) Case (Ms Pagtama): A man in his mid-90s with Stage IV pan-wild-type adenocarcinoma of the lung and a high PD-L1 tumor proportion score who received pembrolizumab monotherapy (50:24) Case (Ms Goodwin): A man in his mid-60s with extensive metastatic adenocarcinoma of the lung who received carboplatin/pemetrexed/pembrolizumab (1:06:52) Immunotherapy as Consolidation After Chemoradiation Therapy for Locally Advanced NSCLC (1:15:58) Case (Ms Pagtama): A man in his early 70s with locally recurrent adenocarcinoma of the lung who received concurrent chemoradiation therapy followed by consolidation durvalumab (1:16:26) Select publications